Trial Profile
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Safety and Insulin-Sparing Efficacy of the Addition of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Insulin Alone or in Combination With Metformin
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary) ; Insulin glargine; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 11 Apr 2019 This trial has been completed in Spain, according to European Clinical Trials Database.
- 15 Sep 2017 Results (n=1299) of pooled analysis of 2 trials (NCT00395343 and NCT01462266) presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes
- 09 Jun 2015 Results of subgroup analysis (assessing incidences of hypoglycaemia) presented at the 75th Annual Scientific Sessions of the American Diabetes Association.